ARCHIVES

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

November 21, 2014

Blacks Half As Likely To Get Surgery For Esophageal Cancer

January 28, 2005

FDA Faces Severe Regulatory, Scientific Needs, Report Finds.

February 1, 2008

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Panel Waffles On One Vs. Three Year Intervals For Pap Test, Agrees On when They Should Start

August 1, 1980

In Brief: NCI Names Rice To Head Frederick Center; NIAID Appoints Killen DAIDS Director

April 22, 1994